Evidence map›GLP-1 receptor agonists × blood pressure›PMID 28129251›Full record

Trial reportJournal of hypertension2017

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.

Preman Kumarathurai, Christian Anholm, Andreas Fabricius-Bjerre, Olav W Nielsen, Ole Kristiansen, Sten Madsbad, Steen B Haugaard, Ahmad Sajadieh

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of hypertension, 2017. The graph read 5 numbers from its abstract, feeding 2 cells of the map: it finds no clear difference in 1. Cited by 18 papers, 4 of them syntheses that pooled it.

5numbers the graph read from it
1cell of the map it votes in
18citing papers in PubMed, 4 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

← favours the treatmentfavours the comparator →
-4.3317.20 · no effect
Mean 24-h DBPliraglutide vs placebono clear difference · hypertension, ascvdfeeds one cell of the map
Δ 4.20-0.74 to 9.17
Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference +1.8 mmHg (95% confidence interval, 95% CI: -4.33 to 7.93)] or DBP [+4.2 mmHg (-0.74 to 9.17)].
FeedsGLP-1 receptor agonists×blood pressure
Evening DBPliraglutide vs placebofavours the comparator · hypertension, ascvdfeeds one cell of the map
Δ 9.703.90 to 15.5
Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2 mmHg (95% CI: 1.1-17.2) and +9.7 mmHg (95% CI: 3.9-15.5), respectively].
FeedsGLP-1 receptor agonists×blood pressure
Mean 24-h SBPliraglutide vs placebono clear difference · hypertension, ascvdfeeds one cell of the map
Δ 1.80-4.33 to 7.93
Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference +1.8 mmHg (95% confidence interval, 95% CI: -4.33 to 7.93)] or DBP [+4.2 mmHg (-0.74 to 9.17)].
FeedsGLP-1 receptor agonists×blood pressure
Evening SBPliraglutide vs placebofavours the comparator · hypertension, ascvdfeeds one cell of the map
Δ 9.201.10 to 17.2
Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2 mmHg (95% CI: 1.1-17.2) and +9.7 mmHg (95% CI: 3.9-15.5), respectively].
FeedsGLP-1 receptor agonists×blood pressure

Read, but not usablea number the graph found but could not read as for or against

Mean heart rateliraglutide vs placebodirection of benefit for this outcome is not defined · hypertension, ascvdfeeds one cell of the map
Δ 7.602.56 to 12.6
Mean heart rate significantly increased after liraglutide [+7.6 bpm (95% CI: 2.56-12.62)].
FeedsGLP-1 receptor agonists×adverse events & safety

clause the extractor read what became the number

2 · Its place on the map

Where it lands on the map

Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.

supports the treatmentfavours the comparatorno clear differenceread, but no usable result
3 · What it changes

What it adds to each cell

For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.

GLP-1 receptor agonists×blood pressure

InconclusiveOpen on the map →What to test next →

10 readable studies in this cell: 4 favour the treatment, 5 find no difference, 1 favour the comparator.

Belief with this paper
0.50contested · 3 families support, 1 contradict · against placebo
Without it
0.50This paper does not move the number.
← favours the treatmentfavours the comparator →
0 · no effect
This paper · 2017
Δ 4.20-0.74 to 9.17
NCT00676338820 enrolled · 2008
Δ 0.36-1.02 to 1.73
NCT00781937422 enrolled · 2008
Treatment Contrast -2.72-4.69 to -0.76
NCT02492763176 enrolled · 2015
Δ -1.10-6.20 to 4.10
Effects of Semaglutide on Body Composition and GFR: A Prespecified Ana…PMID 42308057 · 125 enrolled · 2022
change -0.90-1.60 to -0.10
NCT04019197108 enrolled · 2019
β coefficient -0.05-0.10 to -0.01
NCT0488111060 enrolled · 2021
Δ -0.00-5.80 to 5.80
The effects of GLP-1 based therapies on postprandial haemodynamics: Tw…PMID 28086201 · 2017
Δ 684439 to 929
Effect of liraglutide on ambulatory blood pressure in patients with hy…PMID 30242948 · 2019
Δ -1.42-4.25 to 1.40
Heart rate acceleration with GLP-1 receptor agonists in type 2 diabete…PMID 27777261 · 2017
Δ -12.6

GLP-1 receptor agonists×adverse events & safety

No readable resultOpen on the map →What to test next →

40 readable studies in this cell: 47 favour the treatment, 14 find no difference, 2 favour the comparator.

Belief with this paper
0.02contested · 1 family supports, 41 contradict · against placebo
Without itNot a counted family in this claim, so removing it changes nothing.
← favours the treatmentfavours the comparator →
0 · no effect
NCT017204463,297 enrolled · 2013
Δ -0.66-0.80 to -0.52
NCT036893742,274 enrolled · 2018
Δ -0.29-0.38 to -0.20
NCT013360231,663 enrolled · 2011
Treatment contrast -0.64-0.75 to -0.53
NCT040178321,441 enrolled · 2019
Δ -0.20-0.30 to -0.10
NCT018365231,398 enrolled · 2013
Δ -0.20-0.32 to -0.07
NCT019301881,231 enrolled · 2013
Δ -1.06-1.21 to -0.91
NCT007344741,202 enrolled · 2008
Δ -0.71-0.87 to -0.55
NCT008389031,049 enrolled · 2009
Δ -0.91-1.16 to -0.65
NCT009606611,036 enrolled · 2009
Δ -0.04-0.18 to 0.11
NCT050350821,018 enrolled · 2021
Δ -0.24-0.44 to -0.04
NCT01064687978 enrolled · 2010
Δ -1.05-1.22 to -0.88
NCT01117350978 enrolled · 2010
Δ 2.54-3.88 to 8.93

This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.

4 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

5 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Observational
  11. Glucagon-like peptide 1 (GLP-1).Molecular metabolism · 2019 · on this map
    Review
  12. Review
  13. Article
  14. Article
  15. Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials.Journal of community hospital internal medicine perspectives · 2018
    Review
  16. Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017
    Article
  17. Article
  18. Article
6 · The record

Corrections and comments

7 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Preman KumarathuraiaDepartment of Cardiology, Copenhagen University Hospital of Bispebjerg bDepartment of Internal Medicine, Copenhagen University Hospital of Amager cDepartment of Endocrinology, Copenhagen University Hospital of Hvidovre dClinical Research Center, Copenhagen University Hospital of Hvidovre, Copenhagen, Denmark.
Christian Anholm
Andreas Fabricius-Bjerre
Olav W Nielsen
Ole Kristiansen
Sten Madsbad
Steen B Haugaard
Ahmad Sajadieh
Bispebjerg Hospital · DKAmager Hospital · DKCopenhagen University Hospital · DKHvidovre Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

8 · The paper itself

Abstract

The marked sentences are the ones the graph read a number from.

objectiveThe glucagon-like peptide-1 receptor agonist liraglutide has been shown to reduce blood pressure (BP) in clinical trials using office BP measurements. However, the effects of liraglutide on 24-h BP and on the diurnal variation in BP have not been explored sufficiently.

methodsForty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study. Ambulatory blood pressure monitoring (ABPM) was performed at the start and end of each intervention.

resultsTwenty-four individuals completed all 24-h BP measurements. Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference +1.8 mmHg (95% confidence interval, 95% CI: -4.33 to 7.93)] or DBP [+4.2 mmHg (-0.74 to 9.17)]. Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2 mmHg (95% CI: 1.1-17.2) and +9.7 mmHg (95% CI: 3.9-15.5), respectively]. Mean heart rate significantly increased after liraglutide [+7.6 bpm (95% CI: 2.56-12.62)]. Liraglutide did not affect the BP variability or the nocturnal BP dipping.

conclusionsWe could not demonstrate any BP-lowering effect of liraglutide when using 24-h ABPM. Liraglutide exhibited diurnal variation in the effect on BP without affecting the BP variability or nocturnal BP dipping.

Indexed as

AgedBlood PressureBlood Pressure Monitoring, AmbulatoryCoronary Artery DiseaseCross-Over StudiesDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleGlucagon-Like Peptide-1 Receptor AgonistsHeart RateHumansHypoglycemic AgentsLiraglutideMaleMetforminGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLiraglutideMetformin

Identifiers

PMID28129251
OpenAlexW2584275000

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.